Why the study?
Biodegradable polymer drug-eluting stents promote vessel healing and reduce inflammation compared with durable polymer stents, but their relative efficacy in cardiac allograft vasculopathy required comparison.
Does percutaneous coronary intervention with biodegradable polymer drug-eluting stents reduce clinical events (death or retransplantation) and angiographic revascularization rates compared with durable polymer drug-eluting stents in heart transplant recipients with cardiac allograft vasculopathy?
Does percutaneous coronary intervention with biodegradable polymer drug-eluting stents reduce clinical events (death or retransplantation) and angiographic revascularization rates compared with durable polymer drug-eluting stents in heart transplant recipients with cardiac allograft vasculopathy?
In heart transplant recipients undergoing PCI for cardiac allograft vasculopathy, biodegradable polymer everolimus-eluting stents were associated with a significantly lower risk of target vessel non-target lesion revascularization compared to durable polymer drug-eluting stents, though clinical survival outcomes were similar.
Answers are grounded in this paper and cite their sources.
May reduce TVNLR with BP-DES in cardiac allograft vasculopathy; leaves open need for randomized confirmation.
Background: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is a therapeutic option for cardiac allograft vasculopathy (CAV). Biodegradable polymer (BP)-DES, designed to promote vessel healing and reduce inflammation compared with durable polymer (DP)-DES, has been developed. In this study, we aimed to compare the efficacy of BP-DES and DP-DES in patients with CAV. Methods: In this single-center retrospective study, we evaluated patients with CAV who underwent their first PCI between 2010 and 2024; the patients were categorized into the BP-DES and DP-DES groups. Clinical (all-cause death or heart retransplantation) and angiographic outcomes (in-stent restenosis [ISR], target lesion revascularization [TLR], target vessel revascularization [TVR], target vessel nontarget lesion revascularization [TVNLR], and nontarget vessel revascularization [NTVR]) were assessed. Conclusions: PCI with BP-DES was associated with a lower TVNLR than PCI with DP-DES. Both DES resulted in similar clinical outcomes; however, a long-term investigation is warranted.
No takes yet. Share an insight, caveat, or question.
Tsuji et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: